Skip to main content
Top
Published in: Clinical and Experimental Medicine 4/2020

01-11-2020 | Metastasis | Original Article

The effects of apoptosis and apelin on lymph node metastasis in invasive breast carcinomas

Authors: Munevver Baran, Fıgen Ozturk, Ozlem Canoz, Gozde Ozge Onder, Arzu Yay

Published in: Clinical and Experimental Medicine | Issue 4/2020

Login to get access

Abstract

This study aimed to evaluate the biological and clinical significance of apelin-36 in breast cancer and to compare apelin-36 expression and apoptotic index in both breast tissue and metastatic lymph nodes in patients with invasive breast carcinoma. In this study, both tumor tissue and metastatic lymph nodes of the same patient were collected from 60 cases of invasive breast carcinoma patients (IDC, ILC) and 20 cases of normal breast tissue with no tumor from mammoplasty were used as the control group. The expression of apelin was examined with immunohistochemically, and the apoptotic index was examined with TUNEL methods. According to Kruskal–Wallis analysis, there was a significant difference between IDC and the control group when the apelin expression was compared between the breast tissues (p = 0.001). There were significant differences between the three groups when comparing relationships with apoptotic index (p < 0.001). According to the Mann–Whitney U test, both tumor size and expression of apelin in lymph nodes in ILCs were significantly higher than IDCs. (p = 0.026, p = 0.024, respectively). According to correlation analysis, there was a good correlation between the expression of apelin in breast tissue and apelin expression in lymph nodes (p = 0.000). It is also found a similar relationship in terms of the apoptotic index (p = 0.000). In addition, the negative correlation was found between apelin expression and the apoptotic index in breast tissues (p = 0.003). Based on these results, apelin-36 can be used as a marker for determining the metastasis potential in invasive breast cancer.
Literature
1.
go back to reference Desantis C, Siegel R, Bandi P, et al. Breast cancer statistics. CA Cancer J Clin. 2011;61(6):408–18.CrossRef Desantis C, Siegel R, Bandi P, et al. Breast cancer statistics. CA Cancer J Clin. 2011;61(6):408–18.CrossRef
2.
go back to reference Lu YS, Kuo SH, Huang CS. Recent advances in the management of primary breast cancers. J Formos Med Assoc. 2004;103(8):579–98.PubMed Lu YS, Kuo SH, Huang CS. Recent advances in the management of primary breast cancers. J Formos Med Assoc. 2004;103(8):579–98.PubMed
3.
go back to reference Senkus E, Kyriakides S, Penault-Llorea F, et al. ESMO Guidelines Working Group Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol. 2013;24:7–23.CrossRef Senkus E, Kyriakides S, Penault-Llorea F, et al. ESMO Guidelines Working Group Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol. 2013;24:7–23.CrossRef
4.
go back to reference Stacker SA, Achen MG, Jussila L, et al. Metastasis: Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002;2:573–83.CrossRef Stacker SA, Achen MG, Jussila L, et al. Metastasis: Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002;2:573–83.CrossRef
5.
go back to reference Pitkin SL, Maguire JJ, Bonner TI, et al. International Unıon of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev. 2010;62(3):331–42.CrossRef Pitkin SL, Maguire JJ, Bonner TI, et al. International Unıon of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev. 2010;62(3):331–42.CrossRef
6.
go back to reference Carpene C, Dray C, Attane C, et al. Expanding role for the apelin/APJ system in physiopathology. J Physiol Biochem. 2007;63:359–73.CrossRef Carpene C, Dray C, Attane C, et al. Expanding role for the apelin/APJ system in physiopathology. J Physiol Biochem. 2007;63:359–73.CrossRef
7.
go back to reference Kawamata Y, Habata Y, Fukusumi S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta. 2001;1538:162–71.CrossRef Kawamata Y, Habata Y, Fukusumi S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta. 2001;1538:162–71.CrossRef
8.
go back to reference Liu C, Su T, Li F, et al. PI3K/Akt signaling transduction pathway is involved in rat vascular smooth muscle cell proliferation induced by apelin-13. Acta Biochim Biophys Sin. 2010;42(6):396–402.CrossRef Liu C, Su T, Li F, et al. PI3K/Akt signaling transduction pathway is involved in rat vascular smooth muscle cell proliferation induced by apelin-13. Acta Biochim Biophys Sin. 2010;42(6):396–402.CrossRef
9.
go back to reference Li L, Li L, Xie F, et al. Jagged-1/Notch3 signaling transduction pathway is involved in apelin-13-induced vascular smooth muscle cells proliferation. Acta Biochim Biophys Sin. 2013;45(10):875–81.CrossRef Li L, Li L, Xie F, et al. Jagged-1/Notch3 signaling transduction pathway is involved in apelin-13-induced vascular smooth muscle cells proliferation. Acta Biochim Biophys Sin. 2013;45(10):875–81.CrossRef
10.
go back to reference He L, Xu J, Chen L, et al. Apelin/APJ signaling in hypoxia-related diseases. Clin Chim Acta. 2015;451(Pt B):191–8.CrossRef He L, Xu J, Chen L, et al. Apelin/APJ signaling in hypoxia-related diseases. Clin Chim Acta. 2015;451(Pt B):191–8.CrossRef
11.
go back to reference Cox CM, D’Agostino SL, Miller MK, et al. Apelin the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol. 2006;296(1):177–89.CrossRef Cox CM, D’Agostino SL, Miller MK, et al. Apelin the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol. 2006;296(1):177–89.CrossRef
12.
go back to reference Kasai A, Shintani N, Oda M, et al. Apelin is novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun. 2004;325(2):395–400.CrossRef Kasai A, Shintani N, Oda M, et al. Apelin is novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun. 2004;325(2):395–400.CrossRef
13.
go back to reference Berta J, Hoda MA, Laszlo V, et al. Apelin promotes lymphangiogenesis and lymph node metastasis. Oncotarget. 2014;5(12):4426–37.CrossRef Berta J, Hoda MA, Laszlo V, et al. Apelin promotes lymphangiogenesis and lymph node metastasis. Oncotarget. 2014;5(12):4426–37.CrossRef
14.
go back to reference Rayalam S, Delta-Fera MA, Kasser T, et al. Emerging role of apelin as a therapeutic target in cancer: a patent review. Recent Pat Anticancer Drug Discov. 2011;6(3):367–72.CrossRef Rayalam S, Delta-Fera MA, Kasser T, et al. Emerging role of apelin as a therapeutic target in cancer: a patent review. Recent Pat Anticancer Drug Discov. 2011;6(3):367–72.CrossRef
15.
go back to reference Heo K, Kim YH, Sung HJ, et al. Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients. Oral Oncol. 2012;48(6):500–6.CrossRef Heo K, Kim YH, Sung HJ, et al. Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients. Oral Oncol. 2012;48(6):500–6.CrossRef
16.
go back to reference Lacquaniti A, Altavilla G, Picone A, et al. Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation. Clin Exp Med. 2015;15(1):97–105.CrossRef Lacquaniti A, Altavilla G, Picone A, et al. Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation. Clin Exp Med. 2015;15(1):97–105.CrossRef
17.
go back to reference Medhurst AD, Jennings CA, Robbins MJ, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem. 2003;84:1162–72.CrossRef Medhurst AD, Jennings CA, Robbins MJ, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem. 2003;84:1162–72.CrossRef
18.
go back to reference Peng X, Li F, Wang P, et al. Apelin-13 inducesMCF-7 cell proliferation and invasion via phosphorylation of ERK1/2. Int J Mol Med. 2015;36:733–8.CrossRef Peng X, Li F, Wang P, et al. Apelin-13 inducesMCF-7 cell proliferation and invasion via phosphorylation of ERK1/2. Int J Mol Med. 2015;36:733–8.CrossRef
19.
go back to reference Sorli SC, Le Gonidec S, Knibiehler B, et al. Apelin is a potent activator of tumour neoangiogenesis. Oncogene. 2007;26(55):7692–9.CrossRef Sorli SC, Le Gonidec S, Knibiehler B, et al. Apelin is a potent activator of tumour neoangiogenesis. Oncogene. 2007;26(55):7692–9.CrossRef
20.
go back to reference Wang Z, Greeley GH Jr, Qiu S. Immunohistochemical localization of apelin in human normal breast and breast carcinoma. J Mol Histol. 2008;39(1):121–4.CrossRef Wang Z, Greeley GH Jr, Qiu S. Immunohistochemical localization of apelin in human normal breast and breast carcinoma. J Mol Histol. 2008;39(1):121–4.CrossRef
21.
go back to reference Feng M, Yao G, Yu H, et al. Tumour apelin, not serum apelin, is associated with the clinical features and prognosis of gastric cancer. BMC Cancer. 2016;16:794–802.CrossRef Feng M, Yao G, Yu H, et al. Tumour apelin, not serum apelin, is associated with the clinical features and prognosis of gastric cancer. BMC Cancer. 2016;16:794–802.CrossRef
22.
go back to reference Cevik O, Gergin OO, Yildiz K, et al. The chondrotoxic and apoptotic effects of levobupivacaine and bupivacaine on the rabbit knee joint. Rev Bras Anestesiol. 2018;68(6):605–12.CrossRef Cevik O, Gergin OO, Yildiz K, et al. The chondrotoxic and apoptotic effects of levobupivacaine and bupivacaine on the rabbit knee joint. Rev Bras Anestesiol. 2018;68(6):605–12.CrossRef
23.
go back to reference Rakha EA, El-Sayed ME, Powe DG, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer. 2008;44:73–83.CrossRef Rakha EA, El-Sayed ME, Powe DG, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer. 2008;44:73–83.CrossRef
24.
go back to reference Lee JH, Park S, Park HS, et al. Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study. World J Surg Oncol. 2010;8:34.CrossRef Lee JH, Park S, Park HS, et al. Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study. World J Surg Oncol. 2010;8:34.CrossRef
25.
go back to reference Cabioglu N, Ozmen V, Kaya H, et al. Increased lymph node positivity in multifocal and multicentric breast cancer. J Am Coll Surg. 2009;208(1):67–74.CrossRef Cabioglu N, Ozmen V, Kaya H, et al. Increased lymph node positivity in multifocal and multicentric breast cancer. J Am Coll Surg. 2009;208(1):67–74.CrossRef
26.
go back to reference Sayer HG, Kath R, Kliche KO, et al. Premenopausal breast cancer: chemotherapy and endocrine therapy. Drugs. 2002;62:2025–38.CrossRef Sayer HG, Kath R, Kliche KO, et al. Premenopausal breast cancer: chemotherapy and endocrine therapy. Drugs. 2002;62:2025–38.CrossRef
27.
go back to reference Kelleher M, Miles D. The adjuvant treatment of breast cancer. Int J Clin Pract. 2003;57:195–9.PubMed Kelleher M, Miles D. The adjuvant treatment of breast cancer. Int J Clin Pract. 2003;57:195–9.PubMed
28.
go back to reference de Castro Sant' Anna C, Junior AGF, Soares P, et al. Molecular biology as a tool for the treatment of cancer. Clin Exp Med. 2018; 18(4):457–464. de Castro Sant' Anna C, Junior AGF, Soares P, et al. Molecular biology as a tool for the treatment of cancer. Clin Exp Med. 2018; 18(4):457–464.
29.
go back to reference Newman LA. Epidemiology of locally advanced breast cancer. Semin Radiat Oncol. 2009;19(4):195–203.CrossRef Newman LA. Epidemiology of locally advanced breast cancer. Semin Radiat Oncol. 2009;19(4):195–203.CrossRef
30.
go back to reference Barbour A, Gotley DC. Current concepts of tumour metastasis. Ann Acad Med Singapore. 2003;32:176–84.PubMed Barbour A, Gotley DC. Current concepts of tumour metastasis. Ann Acad Med Singapore. 2003;32:176–84.PubMed
31.
go back to reference Yang Y, Lv SY, Ye W, et al. Apelin/APJ system and cancer. Clin Chim Acta. 2016;457:112–6.CrossRef Yang Y, Lv SY, Ye W, et al. Apelin/APJ system and cancer. Clin Chim Acta. 2016;457:112–6.CrossRef
32.
go back to reference Wang G, Qi X, Wei W, et al. Characterization of the 5’-regulatory regions of the rat and human apelin genes and regulation of breast apelin by USF. FASEB J. 2006;20:2639–41.CrossRef Wang G, Qi X, Wei W, et al. Characterization of the 5’-regulatory regions of the rat and human apelin genes and regulation of breast apelin by USF. FASEB J. 2006;20:2639–41.CrossRef
33.
go back to reference Maden M, Pamuk ON, Pamuk GE. High apelin levels could be used as a diagnostic marker in multiple myeloma: a comparative study. Cancer Biomark. 2016;17:391–6.CrossRef Maden M, Pamuk ON, Pamuk GE. High apelin levels could be used as a diagnostic marker in multiple myeloma: a comparative study. Cancer Biomark. 2016;17:391–6.CrossRef
34.
go back to reference Hu D, Zhu WF, Shen WC, et al. Expression of Apelin and Snail protein in breast cancer and their prognostic significance. Zhonghua Bing Li Xue Za Zhi. 2018;47:743–6.PubMed Hu D, Zhu WF, Shen WC, et al. Expression of Apelin and Snail protein in breast cancer and their prognostic significance. Zhonghua Bing Li Xue Za Zhi. 2018;47:743–6.PubMed
35.
go back to reference Falck AK, Ferno M, Bendahl PO, et al. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer? World J Surg. 2010;34:1434–41.CrossRef Falck AK, Ferno M, Bendahl PO, et al. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer? World J Surg. 2010;34:1434–41.CrossRef
36.
go back to reference Booth A, Magnuson A, Fouts J, et al. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Invest. 2015;21(1):57–74. Booth A, Magnuson A, Fouts J, et al. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Invest. 2015;21(1):57–74.
37.
go back to reference Christodoulatos GS, Syprou N, Kadillari J, et al. The role of adipokines in breast cancer: current evidence and perspectives. Current Obesity Reports. 2019;8:413–33.CrossRef Christodoulatos GS, Syprou N, Kadillari J, et al. The role of adipokines in breast cancer: current evidence and perspectives. Current Obesity Reports. 2019;8:413–33.CrossRef
38.
go back to reference Villar E, Redondo M, Rodrigo I, et al. Bcl-2 Expression and apoptosis in primary and metastatic breast carcinomas. Tumour Biol. 2001;22(3):137–45.CrossRef Villar E, Redondo M, Rodrigo I, et al. Bcl-2 Expression and apoptosis in primary and metastatic breast carcinomas. Tumour Biol. 2001;22(3):137–45.CrossRef
Metadata
Title
The effects of apoptosis and apelin on lymph node metastasis in invasive breast carcinomas
Authors
Munevver Baran
Fıgen Ozturk
Ozlem Canoz
Gozde Ozge Onder
Arzu Yay
Publication date
01-11-2020
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 4/2020
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-020-00635-2

Other articles of this Issue 4/2020

Clinical and Experimental Medicine 4/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.